← Back to Analyst Consensus 
RVMD Buy
Revolution Medicines, Inc.
Current Price —
Implied Upside —
Analysts 29
30-Day Momentum
▲ 2 upgrades / ▼ 0 downgrades / 6 reiterations from 6 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 21, 2026 | TD Cowen | reiterate | Buy → Buy | — | 54% |
| Oct 19, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Oct 16, 2026 | William Blair | initiate | — → Outperform | — | 48% |
| Oct 15, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Oct 14, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Oct 8, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Oct 7, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Sep 28, 2026 | Brookline Capital | initiate | — → Buy | — | 38% |
| Sep 21, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Sep 10, 2026 | Morgan Stanley | initiate | — → Overweight | — | 54% |
| Sep 9, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| Aug 31, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Aug 28, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Aug 28, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 27, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Aug 27, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 27, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Aug 27, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Aug 27, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| Aug 27, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 21, 2026 | Bernstein | maintain | Market Perform → Market Perform | — | 52% |
| Aug 11, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Aug 6, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 6, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Aug 6, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| Aug 6, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 6, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jul 23, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jul 20, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jul 9, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 6, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 6, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jul 2, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jun 30, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Jun 29, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jun 10, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| Jun 2, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jun 1, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 1, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| May 22, 2026 | Bernstein | initiate | — → Market Perform | — | 52% |
| May 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| May 7, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 7, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| May 7, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| May 7, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Apr 22, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 50% |
| Apr 22, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 20, 2026 | Stifel | reiterate | Buy → Buy | — | 53% |
| Apr 20, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Apr 14, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
Price Target Trend
Jul 27, 2026 Latest: $258.84 Oct 25, 2026
EPS Estimates
+1q $-1.98
Lo: $-3.53 Hi: $-0.53
21 analysts ▲2
+1y $-5.76
Lo: $-9.91 Hi: $-1.91
24 analysts ▲2
0q $-2.38
Lo: $-3.24 Hi: $-2.07
21 analysts ▲1
0y $-9.58
Lo: $-12.17 Hi: $-8.21
24 analysts ▲2
Cross-Platform Signals
No cross-platform signals in the last 90 days